CD38 and Miyoshi myopathy: In addition, in a retrospective analysis that included patients from the KarMMa trial, significant improvements with ide-cel compared with other MM therapies (immunomodulatory agent, PIs, and anti-CD38 antibodies) were seen in ORR (76.4% vs 32.2%; p < 0.0001), PFS (11.6 vs 3.5 months; p = 0.0004), and OS (20.2 vs 14.7 months; p = 0.0006) [14].